Brighton Jones’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$997K Sell
16,625
-621
-4% -$39.1K 0.02% 526
2026
Q2
$987K Sell
17,246
-10,533
-38% -$577K 0.02% 514
2026
Q1
$1.57M Buy
+27,779
New +$1.62M 0.03% 330
2025
Q4
– Sell
-26,000
Closed -$1.41M – 161
2025
Q3
$1.41M Buy
26,000
+5,520
+27% +$316K 0.03% 297
2025
Q2
$1.13M Buy
+20,480
New +$1.21M 0.03% 297

Other funds holding BMRN

Brighton Jones's BMRN Position: Q3 2026 in Review

Brighton Jones reduced its BioMarin Pharmaceuticals (BMRN) stake by 3.6% in Q3 2026, selling an estimated $39.1K and leaving 16,625 shares worth $997K. The position accounts for 0.02% of the portfolio, ranked #526.

Brighton Jones first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.57M in Q1 2026. 443 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Brighton Jones held 16,625 shares of BioMarin Pharmaceuticals worth $997K as of Q3 2026.
  • Brighton Jones sold 621 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $39.1K.
  • BioMarin Pharmaceuticals made up 0.02% of Brighton Jones's portfolio in Q3 2026, its #526 holding.
  • Brighton Jones first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Brighton Jones's BioMarin Pharmaceuticals position peaked at $1.57M in Q1 2026.
  • 443 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.